Moderna Inc. (MRNA)
Contact Levi & Korsinsky by October 8, 2024 Deadline to Join Class Action Against Moderna, Inc. (MRNA)
NEW YORK, NY / ACCESSWIRE / August 23, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Moderna Is Being Sued By The Schall Law Firm For Possibly Breaching Securities Law And Stockholders Are Invited To Participate
LOS ANGELES, CA / ACCESSWIRE / August 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 18, 2023 and June 25, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 8, 2024.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 8, 2024 in Moderna, Inc. Lawsuit - MRNA
NEW YORK, NY / ACCESSWIRE / August 23, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
MRNA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Moderna, Inc. to Contact the Firm Today!
NEW YORK, NY / ACCESSWIRE / August 23, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Moderna securities between January 18, 2023, and June 25, 2024, inclusive (the "Class Period").
Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1
CAMBRIDGE, MA / ACCESSWIRE / August 23, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a partial change application for an updated formulation of its COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1. "We appreciate the Ministry of Health, Labour and Welfare approval decision for our updated COVID-19 mRNA vaccine," said Stéphane Bancel, Chief Executive Officer of Moderna.
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Moderna, Inc.(MRNA) Shareholders
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Moderna, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 8, 2024 to Discuss Your Rights - MRNA
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
S&P 500 Gains and Losses Today: Moderna Falls Despite Approval of New COVID Shot
Major U.S. equities indexes fell Thursday as the Jackson Hole Economic Policy Symposium kicked off in Wyoming. Federal Reserve Chair Jerome Powell is scheduled to speak just after the markets open on Friday morning, and his remarks will be under the microscope as investors gauge the timing and magnitude of potential interest rate cuts.
Moderna, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 8, 2024 to Discuss Your Rights – MRNA
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2
Spikevax 2024-2025 formula expected to be available in pharmacies and care settings across the U.S. in the days immediately following approval CAMBRIDGE, MA / ACCESSWIRE / August 22, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Spikevax® (2024-2025 formula) for individuals 12 years and above. Emergency Use Authorization (EUA) for the Moderna's COVID-19 Vaccine (2024-2025 formula) was also granted for individuals 6 months through 11 years of age.
Shareholders that lost money on Moderna, Inc.(MRNA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Shareholders With Losses In Moderna Inc. Are Encouraged To Join A Lawsuit For Securities Fraud With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 18, 2023 and June 25, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 8, 2024.
